Group M-based HIV-1 Gag peptides are frequently targeted by T cells in chronically infected US and Zambian patients

AIDS

Volumn 20, Issue 3, 2006, Pages 353-360

  Bansal, Anju ^a   Gough, Ethan ^a   Ritter, Doug ^a   Wilson, Craig ^a   Mulenga, Joseph ^b   Allen, Susan ^b   Goepfert, Paul A ^a,c,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c University of Alabama at Birmingham   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Ancestral; Consensus; Cross subtype recognition; Gag protein; HIV 1 sequence; Vaccine

Indexed keywords

ANTIGEN; C PEPTIDE; GAG PROTEIN; GAMMA INTERFERON; PROTEIN HXB2; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; UNITED STATES; ZAMBIA;

AIDS VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENES, GAG; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; MALE; T-LYMPHOCYTES; UNITED STATES; ZAMBIA;

EID: 33645028090     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000206501.16783.67     Document Type: Article

References (38)

1. Garber DA, Silvestri G, Feinberg MB. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect Dis 2004; 4:397-413.
2. McMichael AJ, Hanke T. HIV vaccines 1983-2003. Nat Med 2003; 9:874-880.
3. Nabel G, Makgoba W, Esparza J. HIV-1 diversity and vaccine development. Science 2002; 296:2335.
4. Walker BD, Korber BT. Immune control of HIV: the obstacles of HLA and viral diversity. Nat Immunol 2001; 2:473-475.
5. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, et al. HIV-1 nomenclature proposal. Science 2000; 288:55-56.
6. McCutchan FE. Understanding the genetic diversity of HIV-1. Aids 2000; 14 (suppl 3):S31-S44.
7. Coeffier E, Excler JL, Kieny MP, Meignier B, Moste C, Tartaglia J, et al. Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines. AIDS Res Hum Retroviruses 1997; 13:1471-1485.
8. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79:10108-10125.
9. Durali D, Morvan J, Letourneur F, Schmitt D, Guegan N, Dalod M, et al. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients. J Virol 1998; 72:3547-3553.
10. Ferrari G, Humphrey W, McElrath MJ, Excler JL, Duliege AM, Clements ML, et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997; 94:1396-1401.
11. Betts MR, Krowka J, Santamaria C, Balsamo K, Gao F, Mulundu G, et al. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. J Virol 1997; 71:8908-8911.
12. Wilson SE, Pedersen SL, Kunich JC, Wilkins VL, Mann DL, Mazzara GP, et al. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection. AIDS Res Hum Retroviruses 1998; 14:925-937.
13. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415:331-335.
14. Caulfield MJ, Wang S, Smith JG, Tobery TW, Liu X, Davies ME, et al. Sustained peptide-specific gamma interferon T-cell response in rhesus macaques immunized with human immunodeficiency virus gag DNA vaccines. J Virol 2002; 76:10038-10043.
15. Hanke T, McMichael AJ, Mwau M, Wee EG, Ceberej I, Patel S, et al. Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine 2002; 20:1995-1998.
16. Egan MA, Pavlat WA, Tartaglia J, Paoletti E, Weinhold KJ, Clements ML, et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis 1995; 171:1623-1627.
17. Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, Ramshaw IA. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 1998; 72:10180-10188.
18. Dorrell L, Dong T, Ogg GS, Lister S, McAdam S, Rostron T, et al. Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa. J Virol 1999; 73:1708-1714.
19. Thakar MR, Patke D, Lakhashe SK, Bhonge L, Kulkarni SV, Tripathy SP, et al. Consistent subtype-specific anti-HIV type 1 T lymphocyte responses in Indian subjects recently infected with HIV type 1. AIDS Res Hum Retroviruses 2002; 18:1389-1393.
20. Gao F, Korber BT, Weaver E, Liao HX, Hahn BH, Haynes BF. Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev Vaccines 2004; 3:S161-S168.
21. Gao F, Weaver EA, Lu Z, Li Y, Liao HX, Ma B, et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 2005; 79:1154-1163.
22. Nickle DC, Jensen MA, Gottlieb GS, Shriner D, Learn GH, Rodrigo AG, et al. Consensus and ancestral state HIV vaccines. Science 2003; 299:1515-1518; [author reply 1515-1518].
23. Novitsky V, Smith UR, Gilbert P, McLane MF, Chigwedere P, Williamson C, et al. Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design? J Virol 2002; 76:5435-5451.
24. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296:2354-2360.
25. AIDS Vaccine Evaluation Group. Cellular and Humoral Immune Responses to a Canarypox Vaccine Containing Human Immunodeficiency Virus Type 1 Env, Gag, and Pro in Combination with RGP120. J Infect Dis 2001; 183:563-570.
26. Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 1998; 12:2407-2415.
27. Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold K, Sheppard H, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001; 183:1343-1352.
28. Corey L, McElrath MJ, Weinhold K, Matthews T, Stablein D, Graham B, et al. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. J Infect Dis 1998; 177:301-309.
29. Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori D, Corse GJ, et al. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999; 180:290-298.
30. Gupta K, Hudgens M, Corey L, McElrath MJ, Weinhold K, Montefiori DC, et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 2002; 29:254-261.
31. Bansal A, Sabbaj S, Edwards BH, Ritter D, Perkins C, Tang J, et al. T cell responses in HIV type 1-infected adolescent minorities share similar epitope specificities with whites despite significant differences in HLA class I alleles. AIDS Res Hum Retroviruses 2003; 19:1017-1026.
32. Sabbaj S, Bansal A, Ritter GD, Perkins C, Edwards BH, Gough E, et al. Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities. J Acquir Immune Defic Syndr 2003; 33:426-438.
33. Yusim K, Kesmir C, Gaschen B, Addo MM, Altfeld M, Brunak S, et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol 2002; 76:8757-8768.
34. Rutebemberwa A, Currier JR, Jagodzinski L, McCutchan F, Birx D, Marovich M, et al. HIV-1 MN Env 15-mer peptides better detect HIV-1 specific CD8 T cell responses compared with consensus subtypes B and M group 15-mer peptides. AIDS 2005; 19:1165-1172.
35. Fernandez CS, Stratov I, De Rose R, Walsh K, Dale CJ, Smith MZ, et al. Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol 2005; 79:5721-5731.
36. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003; 100:4144-4149.
37. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-312.
38. Bansal A, Gough E, Sabbaj S, Ritter D, Yusim K, Sfakianos G, et al. CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides. AIDS 2005; 19:241-250.